Tadd S. Wessel
Managing Director @ OrbiMed
New York, United States
Tadd S. Wessel is a Managing Director focused on healthcare royalty and structured finance investments. Prior to joining OrbiMed, Mr. Wessel was a Vice President in the Drawbridge Special Opportunities Fund at Fortress Investment Group focused on healthcare investments. Prior to Fortress, he was a Vice President in the healthcare investmentbanking department of Citigroup. Mr. Wessel began his career with Robertson Stephens in San Francisco, where he worked in the life sciences investment banking group. Mr. Wessel holds an AB from Princeton University.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 90%
Last updated:
For AI agents: llms.txt
Industries Tadd S. Wessel invests in
Stages Tadd S. Wessel invests in
Countries Tadd S. Wessel invests in
Investment Focus
Industry
- Biotechnology 7 (70%)
- Health Care 5 (50%)
- Medical Device 3 (30%)
- Health Diagnostics 3 (30%)
- Medical 2 (20%)
Stage
- Series D 2 (20%)
- Post-IPO Equity 2 (20%)
- Series C 1 (10%)
- Series E 1 (10%)
- Debt Financing 1 (10%)
Country
- United States 6 (60%)
- Germany 2 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Palvella Therapeutics
|
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | $37.7M / Series D / Jan 05, 2023 | |
Fennec Pharmaceuticals
|
Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction ofototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo.Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo. | $45M / Post-IPO Equity / Aug 01, 2022 | |
Leukocare
|
Leukocare is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence. | $2.5M / Venture - Series Unknown / Jun 23, 2021 | |
|
Leukocare
|
Leukocare is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence. | $15M / Debt Financing / Jun 23, 2021 | |
Isotopen Technologien München
|
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries haveestablished GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company.Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. | $108.1M / Convertible Note / Apr 22, 2021 | |
Guardant Health
|
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing andrare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad. | $100M / Series D / Jan 07, 2016 | |
Natera
|
Natera specializes in cell-free DNA testing is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. | $54.6M / Series E / May 01, 2013 | |
ClearPoint Neuro
|
ClearPoint Neuro formerly known as MRI Interventions, is a platform neuro company. Its mission is to improve and restore the quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ClearPoint Neuro's current product portfolio include deep-brainstimulation, and biopsy, with future applications of laser ablation, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. | Post-IPO Equity | |
|
ClearPoint Neuro
|
ClearPoint Neuro formerly known as MRI Interventions, is a platform neuro company. Its mission is to improve and restore the quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ClearPoint Neuro's current product portfolio include deep-brainstimulation, and biopsy, with future applications of laser ablation, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. | Post-IPO Equity | |
Persivia
|
Persivia is a healthcare IT company that provides Population health management solution to hospitals, payers and providers. It specializes in the fields of Value Based Care contracts management, Quality reporting, CAre coordination Chronic Care Management, and Clinical analytics to support ACOs, PCMH.The company was founded in 2005 andheadquartered in Marlborough, Massachusetts. | Series C |
Co-Investors
Agent Capital
1 deal together
BioAdvance
1 deal together
Biotechnology Value Fund
1 deal together
Biotechnology Value Fund
1 deal together
Biotechnology Value Fund
1 deal together
Claremont Creek Ventures
1 deal together
About OrbiMed
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.
OrbiMed Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dina Chaya
Partner
|
|||
Kevin Koch
Venture Partner
|
|||
Rishi Gupta
Private Equity Partner
|
|||
Sunny Sharma
Senior Managing Director
|
|||
|
Tadd S. Wessel
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Tadd S. Wessel invest in?
Tadd S. Wessel invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series D and Post-IPO Equity stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Tadd S. Wessel last invest?
The most recent investment recorded for Tadd S. Wessel closed in Jan 2023. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
